KDI Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

KDI Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$12.4M	Buy	+98,471	New	+$12.7M	4.27%	11

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

KDI Capital Partners's XBI Position: Q3 2021 in Review

KDI Capital Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2021: 98,471 shares worth $12.4M. The stake represents 4.27% of the portfolio and ranks #11 among its holdings.

635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

KDI Capital Partners held 98,471 shares of State Street SPDR S&P Biotech ETF worth $12.4M as of Q3 2021.
State Street SPDR S&P Biotech ETF was a new KDI Capital Partners position in Q3 2021.
State Street SPDR S&P Biotech ETF made up 4.27% of KDI Capital Partners's portfolio in Q3 2021, its #11 holding.
635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on KDI Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.